NSE
Divi's Laboratories LimitedDIVISLAB
Divi's Laboratories is a leading API and custom-synthesis manufacturer.
| Key products | Generic APIs, custom synthesis (CDMO) and nutraceuticals. |
|---|---|
| Geography | India serving global pharma. |
| Competitors | Laurus Labs, global API makers. |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹0 Cr
Institutional buyers
2 in / 2 out
High-impact filings
0 · tilt Neutral
Next corporate action
Dividend - Rs 30 Per Share
ex 2026-07-24
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ALKEM | +₹1,013.7 Cr | 13 | — | — | -2 | 6 |
| 2 | DIVISLABThis | — | — | — | — | — | — |
| 3 | CIPLA | — | — | — | — | +19 | 44 |
| 4 | DRREDDY | — | — | — | — | +20 | 46 |
| 5 | SUNPHARMA | — | — | — | — | +15 | 45 |
| 6 | TORNTPHARM | — | — | — | — | — | — |
| 7 | LUPIN | — | — | — | — | — | — |
| 8 | ZYDUSLIFE | — | — | 1 | +1 | — | — |
| 9 | AUROPHARMA | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-07-24ActionDividend - Rs 30 Per ShareDividend
- 2026-06-11FilingDivi's Laboratories Limited has informed the Exchange regarding 'Information regarding deduction of Income taxDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2DividendNeutral
Information regarding deduction of Income tax at source from payment of Dividend for the financial year 2025-26'.
Source PDF →
No bulk/block deals for DIVISLAB in this window.
News & chatter on DIVISLAB
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.